In vitro activity of Cefpirome: A new fourth generation cephalosporin

Indian Journal of Medical Microbiology

Volumn 21, Issue 1, 2003, Pages 52-55

  Chaudhury, A ^a  

^a SRI VENKATESWARA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antibiotic resistance; Cefpirome

Indexed keywords

CEFAZOLIN; CEFOTAXIME; CEFPIROME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE FACILITY; IN VITRO STUDY; INDIA; LABORATORY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT REFERRAL; PSEUDOMONAS; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

EID: 0042420886     PISSN: 02550857     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Seibert G, Limbert M, Winkler I, Dick T. The antimicrobial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison to five other cephalosporins and two aminoglycosides. Infection 1983;11:275-279.
2. Jones RN, Pfaller MA, Allen SD, Gerlach EH, Fuchs PC, Aldridge KE. Antimicrobial activity of cefpirome: an update compared to third generation cephalosporins against nearly 6000 recent clinical isolates from five medical centres. Diagn Microbiol Infect Dis 1991;14:361-364.
3. Ludo V, for the International study group. Epidemiology and sensitivity of 8625 ICU and haematology/ oncology bacterial isolates in Europe. Scand J Infect Dis- suppl 1993;91:14-24.
4. Jacoby GA, Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended spectrum beta-lactamases. Antimicrob Agents Chemother 1990;34:858-862.
5. Stobberingh EE, Houben AW. Inducing capacity and selection of resistant variants of cefpirome (HR 810) in comparison with other beta-lactam compounds. Chemotherapy 1988;34:490-496.
6. Wolff M for The Cefpirome Pneumonia Study Group. Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. Antimicrob Agents Chemother 1998;42:28-36.
7. Wilson WR. The role of fourth generation cephalosporins in the treatment of serious infectious diseases in hospitalised patients. Diagn Microbiol Infect Dis 1998;31:473-477.
8. Chaudhury A. Experience with cefpirome- a newly introduced cephalosporin in India. Abstr A1. Clinical Laboratory 2001;47:594.
9. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC Jr. (Eds.) Colour Atlas and Textbook of Diagnostic Microbiology. 5th ed. (Lippincott, USA) 1997.
10. Collee JG, Fraser AG, Marmion BP, Simmons A. (Eds.) Mackie & McCartney Practical Medical Microbiology. 14th Ed. (Churchill Livingstone, London) 1996.
11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests; Approved Standards, 7th ed. 2000,20:1.
12. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the value of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999;96:1152-1156.
13. Biedenbach DJ, Johnson DM, Jones RN. In vitro evaluation of cefepime and other broad spectrum beta-lactams in eight medical centres in Thailand. The Thailand Antimicrobial Resistance Study group. Diagn Microbiol Infect Dis 1999;35:325-331.
14. Niitsuma K, Saitoh M, Kojmabara M, Kashiwabara N, Aoki T, Tomizawa M, Maeda J, Kosenda T. Antimicrobial susceptibility of Pseudomonas aeruginosa isolates in Fukushima Prefecture. Jpn J Antibiot 2001;54:79-87.
15. Sanghavi SK, Mane MP, Niphadkar KB. Multidrug resistance in Salmonella typhi. Indian J Med Microbiol 1999;17:88-90.
16. Patil MA, Lakshmi V. Antibiotic resistance among Citrobacter spp. from different clinical specimens. Indian J Med Microbiol 2000;18:25-29.